
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Embecta Corp (EMBC)


- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $16.67
1 Year Target Price $16.67
1 | Strong Buy |
0 | Buy |
3 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.2% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 800.66M USD | Price to earnings Ratio 9.64 | 1Y Target Price 16.67 |
Price to earnings Ratio 9.64 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 1.07 | 52 Weeks Range 9.10 - 20.58 | Updated Date 10/17/2025 |
52 Weeks Range 9.10 - 20.58 | Updated Date 10/17/2025 | ||
Dividends yield (FY) 4.32% | Basic EPS (TTM) 1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.58% | Operating Margin (TTM) 35.43% |
Management Effectiveness
Return on Assets (TTM) 3.8% | Return on Equity (TTM) - |
Valuation
Trailing PE 9.64 | Forward PE - | Enterprise Value 2104197796 | Price to Sales(TTM) 0.73 |
Enterprise Value 2104197796 | Price to Sales(TTM) 0.73 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 8.36 | Shares Outstanding 58485119 | Shares Floating 57239386 |
Shares Outstanding 58485119 | Shares Floating 57239386 | ||
Percent Insiders 0.47 | Percent Institutions 102.12 |
Upturn AI SWOT
Embecta Corp

Company Overview
History and Background
Embecta Corp. was spun off from Becton, Dickinson and Company (BD) in April 2022. It focuses on diabetes care, specifically insulin delivery solutions.
Core Business Areas
- Insulin Delivery: Embecta develops, manufactures, and sells a range of pen needles and syringes used by people with diabetes to inject insulin.
Leadership and Structure
Devdatt (Dev) Kurdikar is the CEO. The company has a traditional corporate structure with various departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- Pen Needles: Embecta's pen needles are used with insulin pens for convenient and accurate insulin delivery. They are a leading player in this market with an estimated 25% market share. Competitors include Novo Nordisk, B. Braun, and HTL-Strefa.
- Revenue: Revenues are over $1B
- Insulin Syringes: Embecta's insulin syringes are used for traditional insulin delivery methods. Market share is approximately 20% of this product category. Competitors include B. Braun, Nipro, and Terumo.
Market Dynamics
Industry Overview
The diabetes care market is driven by the increasing prevalence of diabetes globally. The market is competitive, with established players and evolving technologies.
Positioning
Embecta is a leading pure-play diabetes care company focused on insulin delivery. Their competitive advantage lies in their established brand, extensive distribution network, and focus on quality and reliability.
Total Addressable Market (TAM)
The global diabetes market is estimated to be over $100 billion. Embecta is well-positioned to capture a significant share of the insulin delivery segment which is estimated at $4 Billion.
Upturn SWOT Analysis
Strengths
- Leading market position in pen needles and syringes
- Established brand reputation
- Extensive global distribution network
- Focus on quality and reliability
Weaknesses
- Dependence on insulin delivery market
- Limited product diversification
- Vulnerable to technological disruptions (e.g., insulin pumps, continuous glucose monitors)
- High debt load after spin-off
Opportunities
- Expanding into emerging markets
- Developing new insulin delivery technologies
- Acquiring complementary businesses
- Partnerships with insulin manufacturers
Threats
- Increasing competition from established and new players
- Technological advancements that reduce reliance on insulin injections
- Pricing pressures from healthcare providers and payers
- Regulatory changes impacting diabetes care
Competitors and Market Share
Key Competitors
- NVO
- B Braun (Not Traded on US Exchange)
Competitive Landscape
Embecta competes primarily on brand recognition, product quality, and distribution network. Competitors offer a wider range of diabetes care products and services.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the overall growth of the diabetes market. Since spinning off from BD in April 2022 it has seen slow steady growth.
Future Projections: Future growth is projected to be in the low single digits, driven by emerging markets and new product innovations. Analyst estimates vary based on market conditions and company performance.
Recent Initiatives: Recent initiatives include cost-cutting measures, debt reduction, and expanding into new markets.
Summary
Embecta Corp is a major player in the insulin delivery market with strong brand recognition and distribution capabilities. Its high debt level from the spin-off and reliance on the pen needle and insulin syringe markets present challenges. Future success depends on successful debt reduction, cost management, and innovation in a competitive landscape. Embecta needs to look out for disruptuve technologies which can change the market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2100 | Website https://www.embecta.com |
Full time employees 2100 | Website https://www.embecta.com |
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.